News Releases

SEATTLE --(BUSINESS WIRE)--Aug. 5, 2020-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will present at the 2020 Wedbush PacGrow

SEATTLE --(BUSINESS WIRE)--Aug. 4, 2020-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will release second quarter 2020 financial

SEATTLE --(BUSINESS WIRE)--Jul. 24, 2020-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced it has entered into a definitive securities purchase

- ALPN-202 is a first-in-class conditional CD28 costimulator and dual checkpoint inhibitor - SEATTLE --(BUSINESS WIRE)--Jun. 24, 2020-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and

- Alpine Immune Sciences grants AbbVie option to license worldwide rights to ALPN-101,   a phase 2-ready,   first-in-class dual CD28/ICOS costimulation antagonist, building on AbbVie’s commitment to developing novel therapies in Immunology - Alpine Immune Sciences to receive $60 million in an

SEATTLE --(BUSINESS WIRE)--Jun. 15, 2020-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases,   today announced the company will present a poster at the AACR Virtual

-- ALPN-101 was well tolerated and exhibited potent pharmacodynamic activity, enabling Phase 2 development -- SEATTLE --(BUSINESS WIRE)--Jun. 8, 2020-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer

First presentation of Alpine’s Variant Tumor Necrosis Factor (TNF) Receptor Domain (vTD) Program demonstrating expanded applicability of its directed evolution platform SEATTLE --(BUSINESS WIRE)--Jun. 4, 2020-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy

SEATTLE --(BUSINESS WIRE)--May 29, 2020-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced that the company will present two posters at the EULAR

SEATTLE --(BUSINESS WIRE)--May 26, 2020-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced its participation in an analyst-led fireside chat at the